| |
Wednesday, January 11, 2023 | 2:00pm ET Recent advances in natural language processing (NLP) caused an explosion of practical use cases that have now become viable. This webinar for healthcare & life sciences leaders surveys common NLP applications that are being widely deployed, including real world data extraction from pathology & radiology reports, patient risk adjustment & HCC coding, and more. Register now.
|
|
Today's Big NewsJan 5, 2023 |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now.
|
|
| By Angus Liu Thanks to the FDA’s expedited reviews, an RSV prevention market battle between several pharma giants may kick off in 2023. |
|
|
|
By Annalee Armstrong Deaths in a clinical trial for Eisai’s Alzheimer’s drug lecanemab are once again being flagged, this time in a New England Journal of Medicine entry that highlights a potential risk for patients undergoing a certain type of emergency stroke treatment. |
By Dave Muoio A total 16,000 nurses working in eight New York City hospitals voted to authorize a walk-off, though nearly 6,000 have since come to a tentative agreement with NewYork-Presbyterian, Maimonides Health and Richmond University Medical Center. |
By Conor Hale Zimmer Biomet aims to build out its sports medicine portfolio by acquiring Embody, a collagen implant developer focused on repairing tendons, ligaments and torn rotator cuffs. |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now.
|
|
By Kevin Dunleavy Heading into 2023, inflation is the top concern for the pharmaceutical industry, according to a poll of executives conducted by GlobalData Healthcare. The survey, which was taken between Oct. 26 and Nov. 23, showed that executives placed inflation first, drug pricing and reimbursement constraints second, the Ukraine conflict third, and the political divide in the United States fourth among the top challenges hampering the growth of the industry. |
By Annalee Armstrong A day after buzzing Hummingbird Bioscience for an antibody-drug conjugate licensing pact, Synaffix is back with a substantially similar, yet bigger deal. The Singapore and U.S.-headquartered biotech will work with Amgen in a pact valued at up to $2 billion. |
By Andrea Park A newly discovered biomarker that can be calculated by an artificial intelligence algorithm from a routine CT scan could one day make the process of finding an effective cancer treatment much more efficient. |
By Robert King California's Medicaid managed care program awarded plan contracts to five insurers for 2024 as well as imposed new equity and transparency requirements. |
By Zoey Becker Jazz Pharmaceuticals has its eye on generic makers for its cannabis-derived drug it acquired from its GW Pharma buyout. It sued companies such as Teva and MSN for patent infringement over the drug. |
By Annalee Armstrong Roche is making sure its peptide discovery spinout Nimble Therapeutics stays close with a revision of the companies’ development partnership valued at up to $1.1 billion. |
By Andrea Park Volta Medical just got a major power boost: With the close of its recent series B funding round, the French startup has now doubled its lifetime fundraising tally. |
By Annie Burky The U.S. Department of Health and Human Services Office for Civil Rights announced a proposed rule regarding religious discrimination, marking a departure from a contentious, Trump-era rule. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
Fierce podcastsDon't miss an episode |
| | In this week's episode of "Podnosis," we talk about how telehealth exacerbates health inequities. We also discuss the impact of anti-trans legislation on healthcare and what providers can do to break down barriers to care for gender-diverse populations. |
|
|---|
|
|
|
Wednesday, January 25, 2023 | 1:00pm ET In this webinar, you’ll learn about a case study pursued in collaboration with Geneos Therapeutics and Personalis to utilize a tumor-informed ctDNA assay to retrospectively analyze clinical response to a class of personalized immunotherapies developed against tumor-specific neoantigens in advanced hepatocellular cancer (HCC) patients. Register now.
|
|
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
